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Abstract 
Objectives. Despite the efforts of the European Union (EU) to promote voluntary cooperation among 
Health Technology Assessment (HTA) agencies, different reimbursement decisions for the same drug 
are made across European countries. The aim of this paper is to compare the agreement of cancer drug 
reimbursement decisions using inter-rater reliability measures.  
Methods. This study is based on primary data on 161 cancer drug reimbursement decisions from nine 
European countries from 2002 to 2014. To achieve our goal, we use two measures to analyse 
agreement, in other words, congruency: 1) percentage of agreement and 2) the Kappa Score.  
Results. One main conclusion can be drawn from the analysis. There is a weak to medium agreement 
among cancer drug decisions in the European countries analysed (based on the percentage of 
agreement and the Kappa score). England and Scotland show the highest consistency between the two 
measures, showing a medium agreement. These results are in line with previous literature on the 
congruency of HTA decisions.  
Conclusions. This paper contributes to the HTA literature, by highlighting the extent of weak 
agreement among cancer decisions in Europe.  
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1. Introduction 
Many health care systems have Health Technology Assessment (HTA) processes to inform choices 
regarding which services and products to pay for from public resources. Drug reimbursement 
decisions, which usually combine clinical and economic evidence with value judgements, are 
extremely important, not only to patients but also to manufacturers and health care professionals. Drug 
reimbursement processes have attracted attention from several authors. In the literature, one can find 
comparative analyses, i.e. describing a number of different national models [indicatively 1-4], 
descriptive and comparative studies analysing reimbursement decisions [5-13] and empirical analyses 
on HTA decisions [14-18]. 
Despite the efforts of the European Union (EU) to promote voluntary cooperation among Health 
Technology Assessment (HTA) agencies, reimbursement decisions for the same drug differ across 
European countries [e.g. 6,8,11,18]. Diverging HTA decisions mean that a particular treatment is 
covered in one country and not in another. While these decisions can be justified from a policy 
perspective (well-established procedures), often in neighbouring countries, this may be difficult to 
comprehend for the public [8], particularly because the clinical evidence reviewed is largely the same, 
and countries, while not of equal wealth, are of broadly comparable levels of economic development. 
As a result, one might expect broadly similar decisions (positive or negative) on drug reimbursement 
to be taken. However, this is not the case [e.g. 6,8,11,18].  
To find out why these countries reach different conclusions, in our latest work [18], we made a 
methodological contribution to determining the factors that might lead to different drug reimbursement 
decisions on cancer drugs. Results showed significant associations between reimbursement decisions 
and a drug´s estimated cost-effectiveness, the existence of a financial managed entry agreement 
(MEA), a health system based on social health insurance, the condition´s incidence rate and the 
socioeconomic characteristics of the country. 
Following on our previous research, our aim in this paper is to compare the agreement of cancer drug 
reimbursement decisions in a sample of European countries using inter-rater reliability measures. The 
current study is based on primary data on cancer drug reimbursement decisions from nine European 
countries from 2002 to 2014: Belgium, Germany, France, Spain, Sweden, Portugal, Poland, England 
and Scotland. This dataset was collected as part of the ADVANCE-HTA project [11,18]. To achieve 
our goal, we use two inter-rater reliability measures to analyse agreement or congruency: 1) percentage 
of agreement and 2) the Kappa Score. The inter-rater reliability is the degree of agreement among 
raters. It is a score of how much homogeneity or consensus exists in the decision given by various 
parties. In this analysis, rater refers to the HTA agencies or systems. 
The HTA system’s characteristics are the drivers of our findings. Owing to the nature of their system 
(for a review, see [18]), France, Germany and Spain tend to accept all new drugs into the national 
system. Other European countries, such as England, Scotland, Poland and Belgium, have high rates of 
restriction and rejection. Portugal and Sweden have acceptance rates similar to Spain. However, the 
Spanish system is different from the Portuguese and Swedish because it does not formally allow for 
rejection and restriction at the national level, but the different regions enjoy some freedom of 
implementation. The Spanish system introduced the Informe de Posición Terapeutico (IPT), which 
allows a restricted or rejected decision, at the end of 2013. However, our data pre-date its 
implementation. In England, until 2016, when a cancer drug reimbursement decision was negative, 
there was still the option to get it funded through the Cancer Drug Fund (CDF). From 2016 onwards, 
NICE can recommend entry to the CDF. However, the adoption by the CDF is outside of the HTA 
process which we are studying. 
Previous literature using inter-rater reliability measures to examine agreement among decisions finds, 
in most cases, low agreement. However, these studies only consider a few countries and/or few drug-
indications and/or a short time period [8,12,6,19]. In this paper, we look at nine European countries 
and we compare decisions for 161 cancer drug-indications from of the period 2002 to 2014. By 
examining just one therapeutic area, we make the decisions more comparable across the setting. This 
paper contributes to the HTA literature, shedding light on the weak to medium agreement across cancer 
drug reimbursement decisions in Europe.  
The remainder of the paper is structured as follows. Section 2 describes the methods, including the 
definition of the database and the applied statistics. The results are presented in section 3, and the main 
findings are discussed in the final section. 
2. Methods 
2.1. Database 
The current research is based on primary data on cancer drug reimbursement decisions from nine 
European countries from 2002 to 2014: Belgium, Germany, France, Spain, Sweden, Portugal, Poland, 
England and Scotland. The database was restricted to these countries to ensure a formal HTA system 
and public availability of information. The Scottish Medicines Consortium (SMC) was the starting 
point of our study because it appraises all drugs approved by either the Medicine and Healthcare 
Product Regulatory Agency (MHRA) or the European Medicines Agency (EMA). The drugs selected 
were classified under “malignant disease and immunosuppression” on the SMC website. The list of 
drugs was validated by reviewing National Institute for Health and Care Excellence (NICE) decisions 
for any additional observations (especially on further indications for included drugs). This process 
produced 81 drugs and 161 drug-indications (to account for multiple cancer indications of included 
drugs, as reimbursement decisions may vary for different indications of the same drug). Thus, 161 
cancer drug-indications were considered for each country. Cancer was selected because of the high 
level of public interest in these reimbursement decisions, and because many cancer drugs have been 
appraised thus providing a rich dataset. Data was collected during the EU-funded project Advance-
HTA (7th Framework Programme Grant No. 305983). The creation of the dataset is explained in detail 
in two previous studies [11,18]. Supplementary Table 1 presents the data sources. 
This database contains the outcome of the decision and the date when the decision was published. The 
decision outcome describes the final decision regarding the adoption of the technology. We define the 
outcome as Non-Favourable, Favourable with restrictions and Favourable. These are the three main 
categories of the HTA decision. To distinguish between “Favourable with restrictions” and 
“Favourable”, the decision is considered to be restricted only when it differs from the indication 
detailed in the marketing authorisation (e.g. when reimbursement is limited to a sub-population of the 
patients for whom the drug has been authorized). The rate of acceptance, restriction and rejection for 
each year in each country are generated from the individual cancer drug decisions collected for our 
database.  
In order to capture all possible decisions, we included another category in the decision variable: Non-
assessment. This category can be the result of different circumstances, such as the manufacturer 
deciding not to apply for reimbursement or the decision-maker not requiring assessment of the drug 
by the HTA agency.  
In order to get robust results, we have to consider drug-reimbursement decisions which are comparable 
across countries. In other words, the different HTA systems in Europe, incorporate different HTA 
decisions’ definitions. While for Belgium, England, Poland, Portugal, Scotland and Sweden, the 
outcome of the decision comprises all aspects of the reimbursement and it is used to accept or reject 
the new technology, for Germany and France, it just indicates the added value of the drug and is used 
to decide on the type of price agreement. Moreover, for Spain, the national government tends to accept 
all drugs but then, the regions can decide on the level of access. As a result, in the analysis, we compare 
across the six comparable countries and then consider the other three (Germany, France and Spain).  
2.2. Applied Statistics 
We use two inter-rater reliability measures, the percent agreement and the Cohen’s kappa score [20].  
The percent “agreement among raters” is measured by the number of agreed decisions over the total 
decisions. It has been widely used when measuring inter-rater reliability as it is easy to calculate and 
directly interpretable (e.g. [21,6]). However, the percent agreement statistic does not take account of 
the possibility of chance agreement. So, it may overestimate the true agreement among raters [21].  
Cohen [20] suggests the possibility of a false agreement if the agreement is by chance. For instance, 
this chance agreement can arise if the HTA system tends to accept/restrict/reject all drugs, does not 
perform an in-depth assessment (e.g. only clinical assessment) or assessments are not comparable. 
However, McHugh [21] states that if the raters (HTA systems/agencies) are well trained, the percent 
agreement is a realistic measure to determine interrater reliability. 
The Cohen’s kappa coefficient, κ, is a statistic which measures inter-rater agreement for qualitative 
(categorical) items. It ranges from −1 to +1, where 0 represents the amount of agreement that can be 
expected from random chance, and 1 represents perfect agreement between the raters. While kappa 
values below 0 are possible, Cohen notes they are unlikely in practice. If the kappa score is negative, 
it means that the two observers agreed less than would be expected just by chance. As with all 
correlation statistics, the kappa is a standardized value and thus is interpreted the same across multiple 
studies [20,21].  
	
Where Pr(a) represents the actual observed agreement, and Pr(e) is the proportion of units which would 
be expected to agree by chance. The denominator, 1 - Pr(e), reflects the maximum agreement beyond 
chance that would have been possible given the marginal distributions. Note that the sample size 
consists of the number of observations made across which raters are compared. The statistical 
significance of the kappa coefficient is based on the chi-square distribution. 
Cohen suggests the following interpretation of the kappa coefficient [21]: values ≤ 0 as indicating no 
agreement and 0.01–0.20 as none to slight, 0.21–0.40 as fair, 0.41– 0.60 as moderate, 0.61–0.80 as 
substantial, and 0.81–1.00 as almost perfect agreement. However, for healthcare research, McHugh 
[21] argued that the standard interpretation of the kappa score was too mild. For example, 60% 
agreement implies 40% faulty evidence. For healthcare decisions, 40% of the sample evaluations 
disagreed might be considered a serious quality problem. As a result, the author framed a stricter 
interpretation of kappa values for healthcare: κ=0-0.20 no agreement; κ=0.21-0.39 minimal agreement; 
κ=0.40-0.59 weak agreement; κ=0.60-0.79 moderate agreement; κ=0.80-0.90 strong agreement; 
κ>0.90 almost perfect agreement. While McHugh’s [21] threshold was defined in a clinical context, it 
shows that a stricter approach to the evidence is required. This can also hold true for national healthcare 
decision-making, such as HTA decisions. In the results, both thresholds are used for the interpretation. 
However, kappa scores have three limitations or paradoxes [22-24]: 1) for high values of concordance 
low values of kappa can be recorded, 2) asymmetric, imperfectly imbalanced tables have a higher 
kappa than perfectly imbalanced and symmetric tables and 3) if the sample of assessed drug-
indications is different across countries, it finds values that often lead to underestimation of the actual 
concordance present in the data. The first two paradoxes will mainly affect countries that have high 
congruency (in our case those that tend to accept all drugs). Regarding the third paradox, to overcome 
the limitation, a sample of drug-indications was selected that is common to NICE and SMC, two of 
the agencies showing a higher agreement [19]. 
	
3. Results 
Descriptive statistics are presented in Table 1 and Figure 1. This information characterises countries 
as restrictive or not restrictive, e.g. a country that is not restrictive about giving access (Germany, 
France, Spain) or, conversely, a country, which tends to restrict and reject access (England, Scotland, 
Poland and Belgium). The Supplementary Figure 1 reports similar information to Figure 1 but only 
for the assessed drug-indications (that is, removing the non-assessed category).  
Another indicator for the type of HTA system is the non-assessment rate variable. The rate of non-
assessment does not change over time because it is the percentage of non-assessed drug-indications 
out of the 161 drugs for the entire period. In line with the previous variables, Germany, France and 
Spain have a very low rate, assessing nearly all new drugs. Scotland also joins this group; even though 
it has a high rate of restriction and rejection, it assesses nearly all drugs. Sweden, Portugal, Poland and 
England, in contrast, all have a high rate of non-assessment.  
The following tables, Table 2 and 3, show the results of the analysis. First of all, we take into account 
the whole sample (Table 2 and 3), while in the Supplementary Table 2 and 3, we reduce the sample to 
the drug-indications assessed by NICE and SMC. In these tables, we first present the less restrictive 
countries (France, Germany and Spain) and then the rest. Results are nearly the same for both samples.  
For the interpretation of the results of the percent agreement (Table 2), we follow Allen et al [6] 
thresholds. For the first 6 countries (i.e. Belgium, England, Poland, Scotland and Sweden), results 
show in most of the cases a low congruence, apart from Belgium-Portugal, Scotland-England, Sweden-
Belgium and Portugal-Sweden where there is medium congruence. For France, Germany and Spain, 
we can see that there is high congruence among them. Portugal shows high agreements with France 
and Germany, due to the high rate of acceptance in Portugal. However, while for France, the number 
of assessed drug-indications is high, for Germany, it is low (i.e. due to data availability). 
 
We present the results of the kappa score for the whole sample of 161 cancer drug-indications (Table 
3) and for the subsample of 80 drug-indications assessed by NICE and SMC (Supplementary Table 3). 
To interpret the kappa coefficient the McHugh threshold is stricter than the Cohen one. Table 3 is 
highlighted in colours based on the McHugh threshold but the legend also reports the Cohen threshold. 
Results show in most of the cases there is none (McHugh threshold) to slight (Cohen threshold) 
agreement between countries. The closest agreement that we find, even if it is still considered weak to 
moderate, is between England and Scotland. There is minimal to fair agreement for Portugal-Belgium, 
Sweden-Belgium and England-Poland. 
 
4. Discussion 
The main aim of this research was to compare the agreement of cancer drug reimbursement decisions 
in a sample of nine European countries (2002 to 2014) using two inter-rater reliability measures, the 
percentage of agreement and the Kappa Score.  
Our findings present mixed results. While for percentage of agreement the overall results are a medium 
agreement among cancer drug decisions in the nine European countries analysed, the kappa score 
shows weak agreement. The percent agreement is easily calculated and directly interpretable. 
However, it does not take account of the possibility of chance agreement. So, it may overestimate the 
true agreement among raters [21]. While the kappa score takes it into account, it has some limitations 
or paradoxes which may lower the estimate of agreement excessively [21]. Overall, taking into account 
both measures, there is a weak to medium agreement among cancer drug decisions in the European 
countries analysed. 
England and Scotland show the highest consistency between the two measures, showing medium 
agreement. This result was expected because both countries have a rather similar notion of cost-
effectiveness and the incremental cost-effectiveness ratio (ICER) partly (and importantly) determines 
their HTA bodies’ decision, the cost structure of the health services are similar and the comparators 
are usually the same. England and Scotland are followed by Portugal-Belgium and Sweden-Belgium 
but with less agreement. This result might partly be explained by a similar proportion of accepted, 
restricted and rejected decision among these countries.  
For the rest of the countries, there are two main reasons to explain the low agreement. First of all, 
agreement will depend on the assessing rates of the countries. Some countries assess by law all new 
drugs (Scotland, Spain, Germany and France) while others have a different system in place (i.e., 
regarding who initiates the reimbursement process) or a prioritisation policy and, as a result, they have 
a lower assessing rate. Secondly, the nature of the HTA system matters in the final reimbursement 
decision, for instance, the system does not allow for restriction and rejection decisions or there is less 
availability of managed entry agreements [18].  
Comparing the percentage of agreement and the kappa score, one can see for some countries (Spain, 
France and Germany) a high congruence using the percentage of agreement (Table 2) but a non-
agreement when using the kappa score (Table 3). The explanation for these findings is that as France 
and Spain tend to assess all drugs and accept nearly everything, when the kappa is computed with 
respect to another country that also has a high rate of acceptance, such as Portugal or Sweden, most of 
the kappa scores imply false or chance agreement, due to the system characteristics and the calculation 
of the kappa score. Moreover, for Germany, we only had access to few decisions (21) and in all cases, 
they were positive. For this reason, the kappa score is 0 or impossible to calculate. For these three 
countries, the kappa score has a limitation as has been shown in previous literature (paradox 1), i.e., 
for high values of concordance low values of kappa are recorded [22-24]. However, as explained 
above, the results for France, Spain and Germany must be treated cautiously as they are not directly 
comparable to the other six HTA systems. 
Our findings are in line with previous literature looking at congruency of HTA decisions [8,12,6,19]. 
Allen et al [6] used the percentage of agreement and a taxonomy of systems to assess HTA decisions. 
However, results demonstrate less alignment between HTA recommendations and HTA Process 
taxonomic sets. Nicod and Kanavos [8], using the Kappa score, found that 46% of the drug-indication 
pairs studied (287) received diverging recommendations across countries (five countries) and that the 
level of agreement between agencies was poor to moderate. Nicod [12] while looking only at 10 orphan 
drugs, found that six out of ten drugs received diverging HTA recommendations. Kanavos et al. [19] 
also used the Kappa Score and showed a better level of agreement in assessing health technologies in 
a pharmaceutical sample (20 drugs) than in a medical devices and other technologies sample. So, while 
most of the previous studies found low to moderate agreement among HTA decisions, results differ 
depending on the drug sample size, the number of countries and the therapeutic area. In our analysis, 
we focused on one therapeutic area (i.e. to make it comparable), on 161 cancer drug-indication pairs, 
nine countries (taking into account two main sets) and a longer period of analysis 2002-2014. This 
paper contributes to the HTA literature, by highlighting the extent of weak to medium agreement 
among cancer decisions in Europe. 
During the recent years, there has been much effort at the European level to promote voluntary 
cooperation among the HTA agencies. In 2004, EUnetHTA was created and there is currently a new 
proposal for regulation of HTA being discussed in the EU Parliament and the Council [25]. The 
proposed regulation aims to promote the convergence of methods, tools, assessments and cooperation 
among HTA agencies based on a joint clinical assessment. The main objective is to reduce duplication 
and improve the efficiency of the HTA systems. However, even if the EU is trying to have binding 
decisions at the European level, the countries/regions are still concerned about their own competencies. 
So, despite substantial efforts at the EU level to promote voluntary cooperation and sharing of 
assessment, HTA decisions for cancer drugs differ across the EU countries analysed. These diverging 
decisions can be justified from a policy perspective (as they are based on well-established procedures, 
from a patient or societal perspective), however differential access to a particular treatment across 
neighbouring countries may be difficult to understand for the public, particularly in countries with 
comparable levels of health care spending and similar levels of income [8]. However, further research 
is needed to determine the effect of this differential access on health outcomes.  
Although the results are satisfactory, during this research we encountered a number of challenges. One 
limitation is related to data collection and availability. For instance, for Germany, we only had access 
to few decisions. Moreover, to combine the data from each country in a single analysis some 
assumptions were needed (i.e. details on the assumption can be found in [18]). Regarding the methods, 
while the Kappa score is a standard inter-rater reliability measure, it has several limitations. According 
to McHugh [21], the Cohen threshold for the kappa score in healthcare is too mild. We overcome this 
limitation by using both thresholds in the results interpretation.  
In this study, we have only looked at cancer drugs. Future research should also compare across 
therapeutic areas, in order to explore the level of agreement among decisions.  
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Table 1. Descriptive statistics: variables of interest (2002-2014) 
     
1mean	(standard	deviation),	2	(max,min).	Source:	ADVANCE-HTA	dataset,	created	by	the	author	
	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Country Rate of acceptance Rate of restriction Rate of rejection Rate of non-assessment 
Belgium 65.79 (24.06)1 
(12.5, 100)2 
32.10 (21.06) 
(0, 75) 
2.11 (4.21) 
  (0, 12.5) 
19.25 
France 90.93 (12.00) 
(60, 100) 
2.88 (4.76) 
(0, 12.5) 
6.19 (11.07) 
(0, 40) 
4.35 
Germany 100  (0) 
(100, 100) 
0 (0) 
(0, 0) 
0 (0) 
(0, 0) 
0 
Portugal 86.28 (17.27) 
(50, 100) 
5.13 (11.04) 
(0, 33.33) 
8.59 (12.49) 
(0, 33.33) 
72.67 
Poland 60.27 (43.52) 
(0, 100) 
25.76 (31.50) 
(0, 87.5) 
13.97 (15.49) 
(0, 44.44) 
41.61 
Spain 87.74 (23.35) 
(16.67, 100) 
12.26 (23.35) 
(0, 83.33) 
0 (0) 
(0, 0) 
9.94 
Sweden 87.13 (17.52) 
(55.56, 100) 
6.76 (11.14) 
(0, 33.33) 
6.11 (9.39) 
(0, 22.22) 
68.32 
Scotland 25.00 (18.69) 
(0, 50) 
47.84 (31.08) 
(7.14, 100) 
27.17 (21.02) 
(0, 54.55) 
7.2 
England 46.27 (30.46) 
(0, 100) 
25.91 (20.52) 
(0, 66.67) 
27.82 (28.41) 
(0, 87.5) 
36.36 
 Figure 1. Acceptance, restriction and rejection rate + non-assessed rate (2002-2014) 
	
	
					Source:	ADVANCE-HTA	dataset,	created	by	the	author	
	
	
	
	
	
	
	
	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Percentage of agreement for 161 cancer drug-indications (2002-2014) 
 
Agreement in 
HTA decisions 
(assessed 
drugs) Spain Germany France Sweden Scotland Portugal Poland England Belgium 
France 86.18%1 (123) 94.74% (19)  72% (50) 28.83% (111) 79.55% (44) 24.18% (91) 39.33% (89) 59.84% (122) 
Germany 57.14% (14)   68.75% (16) 46.67% (15) 100% (5) 0% (13) 50% (12) 43.75% (16) 
Spain    72.09% (43) 22.83% (92) 73.17% (41) 26.83% (82) 31.98% (74) 58.25% (103) 
Belgium    65.12% (43) 40.40% (99) 65.85% (41) 34.18% (79) 39.51% (81)  
England    39.39% (33) 63.75% (80) 44.83% (29) 45.16% (62)   
Poland    18.92% (37) 37.84% (74) 31.58% (38)    
Portugal    71.43% (21) 38.24% (34)     
Scotland       30.23% (43)           
Sweden                   
Notes:	
1	percent	of	agreed	decisions	and	in	brackets,	the	total	number	of	common	assessed	decisions	in	both	countries.	
>=75%	 High	Congruence	 >=50%	&	<75%	 Medium	Congruence	 <50%	 Low	Congruence	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Kappa Score for 161 cancer drug-indications (2002-2014) 
	
	
KAPPA SCORE Spain Germany France Sweden Scotland Portugal Poland England Belgium 
France 0.1441** 0.0000  -0.0219 0.0165 0.1520** 0.0188 -0.0050 0.0712** 
Germany 0.0000   0.0000 0.0000 N/A 0.0000 0.0000 0.0000 
Spain    0.1254 -0.0483 0.0322 0.0328 -0.0492 0.0229 
Belgium    0.2483** 0.1348*** 0.2807*** 0.0400 0.0834  
England    -0.0015 0.4661*** 0.1111 0.2075***   
Poland    -0.0054 0.0130 0.1534***    
Portugal    -0.1053 0.0165     
Scotland       -0.0644           
Sweden                   
Notes: significance levels: *** p<0.01, ** p<0.05, * p<0.1 
	
McHugh Threshold Cohen Threshold Kappa coefficient 
No Agreement 
No Agreement 
 
 ≤ 0.0 
  
None to Slight 
0.01-0.20 
 
Minimal Agreement Fair Agreement  0.21 - 0.39 
Weak Agreement Moderate Agreement  0.4 - 0.59 
Moderate Agreement Substantial Agreement  0.6 - 0.79 
Strong Agreement Almost Perfect Agreement  0.8 – 0.9 
Almost perfect Agreement Almost Perfect Agreement > 0.9 
	
	
 
